Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Sodium chloride 0.45% (half-normal saline) is an isotonic crystalloid solution that provides sodium and chloride ions to maintain or restore extracellular fluid volume. It expands intravascular volume, corrects electrolyte imbalances, and can dilute plasma osmolality. The chloride component helps maintain acid-base balance.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous; adult: 500-1000 mL at a rate of 50-100 mL/hour (maintenance); adjust based on fluid and electrolyte status.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable; sodium and chloride ions are endogenous substances with rapid renal regulation; no defined half-life.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >90% as sodium and chloride ions; negligible biliary/fecal elimination.
Category C
Category A/B
Electrolyte
Electrolyte